| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adekola O Alao, Kamna Malhotra, Mantosh J Dewa. Comparing the side effect profile of the atypical antipsychotics. West African journal of medicine. vol 21. issue 4. 2003-04-22. PMID:12665274. |
post clozapine, the food and drug administration (fda) has approved the use of four newer atypical antipsychotics; risperidone, olanzapine, quetiapine and ziprasidone for the treatment of schizophrenia. |
2003-04-22 |
2023-08-12 |
Not clear |
| Steffen H Kristensen, Niels K Pørkse. [Clozapine and diabetic ketoacidosis]. Ugeskrift for laeger. vol 165. issue 5. 2003-04-10. PMID:12599849. |
we report a case of diabetic ketoacidosis in a 54-year-old white female with type 2 diabetes and schizophrenia during clozapine treatment. |
2003-04-10 |
2023-08-12 |
Not clear |
| Scott P Baymiller, Patricia Ball, Robert P McMahon, Robert W Buchana. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophrenia research. vol 59. issue 1. 2003-04-09. PMID:12413642. |
fifty subjects met the dsm-iii-r criteria for schizophrenia or schizoaffective disorder, participated in a 10-week, double-blind comparison of haloperidol and clozapine and a 1-year, open-label clozapine trial, and had available serum glucose and lipid levels. |
2003-04-09 |
2023-08-12 |
human |
| Ana García-Osta, Diana Frechilla, Joaquín Del Rí. Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 1. 2003-04-01. PMID:12551723. |
since hsp70 has been associated to some schizophrenia symptoms, we suggest that reduced hsp70 in the prefrontal cortex, a cortical area that plays a critical role in the etiology of many schizophrenia symptoms, may be linked to an atypical profile of antipsychotics, such as clozapine, and possibly also abaperidone. |
2003-04-01 |
2023-08-12 |
rat |
| Veena Kumari, Tonmoy Sharm. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology. vol 162. issue 2. 2003-03-26. PMID:12110987. |
currently, available data on the differential effects of typical and atypical antipsychotics suggest that atypical antipsychotics, in particular clozapine and risperidone, may be more effective than typical antipsychotics in improving ppi deficits in schizophrenia. |
2003-03-26 |
2023-08-12 |
Not clear |
| Michael Mueck-Weymann, Thomas Rechlin, Franz Ehrengut, Robert Rauh, Jens Acker, Ralf W Dittmann, Jörg Czekalla, Peter Joraschky, Dominique Musselma. Effects of olanzapine and clozapine upon pulse rate variability. Depression and anxiety. vol 16. issue 3. 2003-03-21. PMID:12415532. |
twenty patients with schizophrenia (according to dsm-iii-r criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. |
2003-03-21 |
2023-08-12 |
Not clear |
| A Sénéchal, P Landry, R Deschamps, M Lessar. [Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs]. L'Encephale. vol 28. issue 6 Pt 1. 2003-03-21. PMID:12506270. |
clozapine is an atypical antipsychotic known for its efficacy in refractory schizophrenia. |
2003-03-21 |
2023-08-12 |
Not clear |
| Johanna K Simosky, Karen E Stevens, Lawrence E Adler, Robert Freedma. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology. vol 165. issue 4. 2003-03-20. PMID:12459928. |
the atypical antipsychotic clozapine also normalizes this deficit in schizophrenia patients, but by an unknown mechanism. |
2003-03-20 |
2023-08-12 |
mouse |
| Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Leslie Citrome, Brian Sheitman, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American journal of psychiatry. vol 160. issue 2. 2003-03-04. PMID:12562575. |
the authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. |
2003-03-04 |
2023-08-12 |
Not clear |
| D Mancama, M J Arranz, J Munro, S Osborne, A Makoff, D Collier, R Kerwi. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neuroscience letters. vol 333. issue 3. 2003-01-30. PMID:12429384. |
investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. |
2003-01-30 |
2023-08-12 |
Not clear |
| Michele Fabrazzo, Silvestro La Pia, Palmiero Monteleone, Giuseppina Esposito, Antonio Pinto, Luigi De Simone, Rachele Bencivenga, Mario Ma. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 27. issue 6. 2003-01-24. PMID:12464462. |
in the present study, we assessed prospectively the clinical response to clozapine and the plasma levels of the drug and its major metabolites in 32 drug-resistant patients with schizophrenia kept on a fixed dose of 600 mg/day for 1 year four of the patients met response criteria at week 4 of treatment. |
2003-01-24 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Larry Alphs, Alan I Green, A Carlo Altamura, Ravi Anand, Alberto Bertoldi, Marc Bourgeois, Guy Chouinard, M Zahur Islam, John Kane, Ranga Krishnan, J P Lindenmayer, Steven Potki. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of general psychiatry. vol 60. issue 1. 2003-01-23. PMID:12511175. |
clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (intersept). |
2003-01-23 |
2023-08-12 |
Not clear |
| G Adler, S Grieshaber, V Faude, B Thebaldi, H Dressin. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. Pharmacopsychiatry. vol 35. issue 5. 2003-01-17. PMID:12237790. |
clozapine in patients with chronic schizophrenia: serum level, eeg and memory performance. |
2003-01-17 |
2023-08-12 |
Not clear |
| Cara L Alfaro, Marianne Wudarsky, Rob Nicolson, Peter Gochman, Alexandra Sporn, Marge Lenane, Judith L Rapopor. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of child and adolescent psychopharmacology. vol 12. issue 2. 2003-01-03. PMID:12188977. |
patients with a diagnostic and statistical manual of mental disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15.4 +/- 8.1 mg/day [0.27 +/- 0.15 mg/kg/day]), clozapine (n = 30, mean dose 269.9 +/- 173.3 mg/day [4.4 +/- 2.6 mg/kg/day]), or olanzapine (n = 12, mean dose 17.5 +/- 2.8 mg/day [0.30 +/- 0.13 mg/kg/day]). |
2003-01-03 |
2023-08-12 |
Not clear |
| Stephen R Marder, Susan M Essock, Alexander L Miller, Robert W Buchanan, John M Davis, John M Kane, Jeffrey Lieberman, Nina R Schoole. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia bulletin. vol 28. issue 1. 2002-12-19. PMID:12047022. |
the group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: first generation (fgas) and second generation (sgas) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on fgas and sgas; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics. |
2002-12-19 |
2023-08-12 |
Not clear |
| S Iverson, N Zahid, J P Uetrech. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chemico-biological interactions. vol 142. issue 1-2. 2002-12-19. PMID:12399162. |
dmp 406 is a clozapine analogue developed by dupont-pharma for the treatment of schizophrenia. |
2002-12-19 |
2023-08-12 |
Not clear |
| Kent Jardemark, Marie-Louise Wadenberg, Pernilla Grillner, Torgny H Svensso. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054059. |
the findings that dopamine d3 and d4 receptors are highly expressed in limbic and cortical areas (d4 more than d3), and the fact that the atypical drug clozapine has preferential affinity for the d4 receptors have suggested an involvement of these receptors in schizophrenia. |
2002-12-17 |
2023-08-12 |
Not clear |
| K P Hayhurst, P Brown, S W Lewi. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. Journal of psychopharmacology (Oxford, England). vol 16. issue 2. 2002-12-17. PMID:12095076. |
these findings suggest that clozapine is a clinically and cost-effective intervention for severe schizophrenia in routine clinical settings. |
2002-12-17 |
2023-08-12 |
Not clear |
| K Alptekin, B B Kivirci. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. International clinical psychopharmacology. vol 17. issue 5. 2002-12-03. PMID:12177588. |
we report three patients with schizophrenia who demonstrated improvement of tardive dyskinesia following treatment with quetiapine; two of them were unable to use clozapine because of intolerable side-effects. |
2002-12-03 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Jeffrey A Lieberman, Leslie Citrome, Brian Sheitman, Miranda Chakos, Joseph P McEvo. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. The Journal of clinical psychiatry. vol 63. issue 10. 2002-11-15. PMID:12416603. |
we present an open-label prospective 14-week trial with olanzapine in patients with schizophrenia and schizoaffective disorder whose treatment resistance to clozapine, olanzapine, risperidone, and haloperidol had been determined prospectively. |
2002-11-15 |
2023-08-12 |
Not clear |